• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PACLITAXEL Drug Record

  • Summary
  • Interactions
  • Claims
  • PACLITAXEL chembl:CHEMBL428647 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    NSC-125973
    BMS-181339-01
    TAXOL 100
    ABRAXANE
    DHP 107
    NK 105
    ABI-007
    TAXOL
    BMS 181339-01
    QW-8184
    MBT 0206
    PACITAXEL
    PAXENE
    PACLITAXEL
    INTAXEL
    CAPXOL
    MITOTAX
    CYCLOPAX
    GENEXOL
    LIPOPAC
    ANZATAX
    ONXOL
    TAXALBIN
    GENETAXYL
    TAXOL A
    PLAXICEL
    YEWTAXAN
    5BETA,20-EPOXY-1,2-ALPHA,4,7BETA,10BETA,13ALPHA-HEXAHYDROXYTAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYLISOSERINE
    EBETAXEL
    chembl:CHEMBL428647
    drugbank:01229
    rxcui:56946
    chemidplus:33069-62-4
    pubchem.compound:36314

    Drug Info:

    Year of Approval 1992
    Drug Class antineoplastic agents
    Drug Indications for treatment of peripheral arterial disease (PAD)
    Drug Indications antiinflammatory agent,DMARD
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (11 More Sources)

    Publications:

    Bio M et al., 2013, Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry., J Med Chem
    Vine KL et al., 2007, An investigation into the cytotoxicity and mode of action of some novel N-alkyl-substituted isatins., J Med Chem
    Asami Y et al., 2012, Protuboxepin A, a marine fungal metabolite, inducing metaphase arrest and chromosomal misalignment in tumor cells., Bioorg Med Chem
    O'Boyle NM et al., 2014, β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand., J Med Chem
    Sathish Kumar B et al., 2014, Synthesis of neolignans as microtubule stabilisers., Bioorg Med Chem
    Zhao Y et al., 2013, Dual-functional abeo-taxane derivatives destabilizing microtubule equilibrium and inhibiting NF-κB activation., J Med Chem
    Kamal A et al., 2014, Synthesis and biological evaluation of 4-aza-2,3-dihydropyridophenanthrolines as tubulin polymerization inhibitors., Bioorg Med Chem Lett
    Kumar AS et al., 2013, Design and synthesis of biaryl aryl stilbenes/ethylenes as antimicrotubule agents., Eur J Med Chem
    Parrino B et al., 2015, Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action., Eur J Med Chem
    Tu HY et al., 2009, Ursolic acid derivatives induce cell cycle arrest and apoptosis in NTUB1 cells associated with reactive oxygen species., Bioorg Med Chem
    Kumar M et al., 2013, Tubulin inhibitors from an endophytic fungus isolated from Cedrus deodara., J Nat Prod
    Rai et al., 2006, Effect of the ET(B) receptor agonist, IRL-1620, on paclitaxel plasma pharmacokinetics of breast tumor rats., Exp. Biol. Med. (Maywood)
    Sawers et al., 2014, Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines., Br. J. Cancer
    Cheung et al., 2009, Survivin counteracts the therapeutic effect of microtubule de-stabilizers by stabilizing tubulin polymers., Mol. Cancer
    Kovács et al., 2007, Effects of taxol treatment on the microtubular system and mitochondria of Tetrahymena., Cell Biol. Int.
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Horwitz, 1992, Mechanism of action of taxol., Trends Pharmacol. Sci.
    Qiu et al., 2005, Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death., Int. J. Oncol.
    Zhang et al., 2004, [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro]., Zhonghua Fu Chan Ke Za Zhi
    Gréen et al., 2006, mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy., Clin. Cancer Res.
    Spletstoser JT et al., 2006, Single-site chemical modification at C10 of the baccatin III core of paclitaxel and Taxol C reduces P-glycoprotein interactions in bovine brain microvessel endothelial cells., Bioorg Med Chem Lett
    Nanovskaya et al., 2005, Role of P-glycoprotein in transplacental transfer of methadone., Biochem. Pharmacol.
    Ibrado et al., 1997, Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells., Cancer Res.
    Qian J et al., 2012, Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment., Chest
    Lee SY et al., 2014, Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy., Eur J Cancer
    McWhinney-Glass S et al., 2013, Cumulative genetic risk predicts platinum/taxane-induced neurotoxicity., Clin Cancer Res
    Gately et al., 1996, Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153., Br. J. Cancer
    Ueno et al., 2006, Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin., Cancer Lett.
    Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci
    Brown CC et al., 2014, Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines., Pharmacogenomics
    Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.
    Lu et al., 2002, The effect of paclitaxel on gene expression and activity of arylamine N-acetyltransferase and DNA-2-aminofluorene adduct formation in human leukemia HL-60 cells., Food Chem. Toxicol.
    Abraham JE et al., 2014, Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel., Clin Cancer Res
    Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics
    O'Brien et al., 2008, Functional genomics identifies ABCC3 as a mediator of taxane resistance in HER2-amplified breast cancer., Cancer Res.
    Kwak et al., 2015, Molecular Heterogeneity and Receptor Coamplification Drive Resistance to Targeted Therapy in MET-Amplified Esophagogastric Cancer., Cancer Discov
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Anbalagan et al., 2012, Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts., Mol. Cancer Ther.
    Romero-Benitez et al., 2004, In vivo erythroid recovery following paclitaxel injury: correlation between GATA-1, c-MYB, NF-E2, Epo receptor expressions, and apoptosis., Toxicol. Appl. Pharmacol.
    Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
    Yoshino et al., 2006, Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy., Clin. Cancer Res.
    Matsuyoshi et al., 2006, Bcl-2 phosphorylation has pathological significance in human breast cancer., Pathobiology
    Gan et al., 2006, Expression of basic fibroblast growth factor correlates with resistance to paclitaxel in human patient tumors., Pharm. Res.
    Thomadaki et al., 2006, Treatment of MCF-7 cells with taxol and etoposide induces distinct alterations in the expression of apoptosis-related genes BCL2, BCL2L12, BAX, CASPASE-9 and FAS., Biol. Chem.
    Zhang et al., 2007, Anti-apoptotic role of TWIST and its association with Akt pathway in mediating taxol resistance in nasopharyngeal carcinoma cells., Int. J. Cancer
    Vilmar et al., 2013, Predictive impact of RRM1 protein expression on vinorelbine efficacy in NSCLC patients randomly assigned in a chemotherapy phase III trial., Ann. Oncol.
    Harmsen et al., 2009, Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor., Cancer Chemother. Pharmacol.
    Pereira D et al., 2016, Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile., Eur J Clin Pharmacol
    Menendez et al., 2005, Pharmacological and small interference RNA-mediated inhibition of breast cancer-associated fatty acid synthase (oncogenic antigen-519) synergistically enhances Taxol (paclitaxel)-induced cytotoxicity., Int. J. Cancer
    Foster et al., 2015, The Selective PI3K Inhibitor XL147 (SAR245408) Inhibits Tumor Growth and Survival and Potentiates the Activity of Chemotherapeutic Agents in Preclinical Tumor Models., Mol. Cancer Ther.
    Thanapprapasr et al., 2015, PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer., Mol. Cancer Ther.
    Hyman et al., 2015, Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors., Cancer Chemother. Pharmacol.
    Boyle et al., 2001, The experimental neuroprotectant leukaemia inhibitory factor (LIF) does not compromise antitumour activity of paclitaxel, cisplatin and carboplatin., Cancer Chemother. Pharmacol.
    Janku et al., 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors., Mol. Cancer Ther.
    Guarneri et al., 2015, Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer., Oncologist
    Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.
    Yu et al., 2015, Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092., PLoS ONE
    Knuefermann et al., 2003, HER2/PI-3K/Akt activation leads to a multidrug resistance in human breast adenocarcinoma cells., Oncogene
    Mu et al., 2014, AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models., J. Exp. Clin. Cancer Res.
    Satoh et al., 2014, Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study., J. Clin. Oncol.
    Awada et al., 2016, Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial., JAMA Oncol
    Jordan et al., 2016, HER2 expression identifies dynamic functional states within circulating breast cancer cells., Nature
    Fader AN et al., 2018, Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu., J Clin Oncol
    Yang et al., 2003, p21 Waf-1 (Cip-1) enhances apoptosis induced by manumycin and paclitaxel in anaplastic thyroid cancer cells., J. Clin. Endocrinol. Metab.
    Hegde et al., 2013, Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer., Sci Transl Med
    Hu L et al., 2016, Genetic variation of CYP3A5 influences paclitaxel/carboplatin-induced toxicity in Chinese epithelial ovarian cancer patients., J Clin Pharmacol
    Leskelä S et al., 2011, Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity., Pharmacogenomics J
    García-Martín et al., 2006, Acquired resistance to the anticancer drug paclitaxel is associated with induction of cytochrome P450 2C8., Pharmacogenomics
    Wilson et al., 2016, Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma., Clin. Cancer Res.
    Eberhard et al., 2005, Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib., J. Clin. Oncol.
    Ratner et al., 2012, A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer., Oncogene
    Fedier et al., 2003, The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells., Int. J. Oncol.
    Oizumi S et al., 2012, Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial., Oncologist
    Han et al., 2012, First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung., J. Clin. Oncol.
    Rosell et al., 2012, Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial., Lancet Oncol.
    Goto K et al., 2012, Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer., J Thorac Oncol
    Zhou et al., 2011, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study., Lancet Oncol.
    Maemondo et al., 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR., N. Engl. J. Med.
    Mitsudomi et al., 2010, Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial., Lancet Oncol.
    Mok et al., 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma., N. Engl. J. Med.
    Xu et al., 2015, Proteomic Profiling of Paclitaxel Treated Cells Identifies a Novel Mechanism of Drug Resistance Mediated by PDCD4., J. Proteome Res.
    Goebel et al., 2006, Tubulin polymerization modulates interleukin-2 receptor signal transduction in human T cells., J. Recept. Signal Transduct. Res.
    Marcath LA et al., 2019, Patients carrying CYP2C8*3 have shorter systemic paclitaxel exposure., Pharmacogenomics
    Hui et al., 1998, Inhibition of activator protein 1 activity by paclitaxel suppresses interleukin-1-induced collagenase and stromelysin expression by bovine chondrocytes., Arthritis Rheum.
    Mabuchi et al., 2002, Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel., J. Biol. Chem.
    Bosó V et al., 2014, SNPs and taxane toxicity in breast cancer patients., Pharmacogenomics
    Bellmunt J et al., 2007, Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy., Ann Oncol
    Bang et al., 2015, Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer., J. Clin. Oncol.
    Greenberg et al., 2005, Paclitaxel induces the phosphorylation of the eukaryotic translation initiation factor 4E-binding protein 1 through a Cdk1-dependent mechanism., Oncogene
    Baldwin RM et al., 2012, A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101., Clin Cancer Res
    Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.
    Nakajima Y et al., 2006, Impact of the haplotype CYP3A4*16B harboring the Thr185Ser substitution on paclitaxel metabolism in Japanese patients with cancer., Clin Pharmacol Ther
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Apellániz-Ruiz M et al., 2015, Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy., Clin Cancer Res
    Westerlund et al., 1997, Ovarian cancer cell invasion is inhibited by paclitaxel., Clin. Exp. Metastasis
    Bachmann HS et al., 2015, The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients., Br J Clin Pharmacol
    Li et al., 2007, Downregulation of Bim by brain-derived neurotrophic factor activation of TrkB protects neuroblastoma cells from paclitaxel but not etoposide or cisplatin-induced cell death., Cell Death Differ.
    Stoeck et al., 2014, Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma., Cancer Discov
    Park HS et al., 2016, Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy., Pharmacogenet Genomics
    Mbatchi LC et al., 2015, Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination., Pharmacogenomics
    Oguri et al., 2008, MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer., Mol. Cancer Ther.
    Lee et al., 1997, Identification of tumor-specific paclitaxel (Taxol)-responsive regulatory elements in the interleukin-8 promoter., Mol. Cell. Biol.
    Yu et al., 2015, Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules., Cancer Cell
    Boora GK et al., 2016, Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance)., Cancer Med
    Guo Q et al., 2015, Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--response., Clin Cancer Res
    Apellániz-Ruiz M et al., 2015, Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel--letter., Clin Cancer Res
    Balko et al., 2016, Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence., Sci Transl Med
    Sato Y et al., 2011, Genome-wide association study on overall survival of advanced non-small cell lung cancer patients treated with carboplatin and paclitaxel., J Thorac Oncol
    Russo et al., 2006, E2F-1 overexpression in U2OS cells increases cyclin B1 levels and cdc2 kinase activity and sensitizes cells to antimitotic agents., Cancer Res.
    Takahashi et al., 2005, Cyclin A-associated kinase activity is needed for paclitaxel sensitivity., Mol. Cancer Ther.
    Anand et al., 2003, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol., Cancer Cell
    Gandara et al., 2009, Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics., J. Clin. Oncol.
    Santibáñez M et al., 2013, The MAD1 1673 G → A polymorphism alters the function of the mitotic spindle assembly checkpoint and is associated with a worse response to induction chemotherapy and sensitivity to treatment in patients with advanced epithelial ovarian cancer., Pharmacogenet Genomics
    Werner et al., 2014, Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer., PLoS ONE
  • PACLITAXEL   STMN1

    Interaction Score: 1.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24587245


    Sources:
    CIViC

  • PACLITAXEL   FGD4

    Interaction Score: 1.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22843789


    Sources:
    PharmGKB

  • PACLITAXEL   EIF4EBP1

    Interaction Score: 1.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15897904


    Sources:
    NCI

  • PACLITAXEL   PDCD4

    Interaction Score: 1.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25928036


    Sources:
    CIViC

  • PACLITAXEL   NFE2

    Interaction Score: 1.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14761679


    Sources:
    NCI

  • PACLITAXEL   SPATA5

    Interaction Score: 1.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24444404


    Sources:
    PharmGKB

  • PACLITAXEL   EPHA5

    Interaction Score: 1.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26763541 26133777 26133776 22843789


    Sources:
    PharmGKB

  • PACLITAXEL   MAD1L1

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23407047


    Sources:
    PharmGKB

  • PACLITAXEL   DSCAM

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21079520


    Sources:
    PharmGKB

  • PACLITAXEL   MYB

    Interaction Score: 0.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15001837


    Sources:
    NCI

  • PACLITAXEL   TUBB4A

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC

  • PACLITAXEL   TUBA3C

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC

  • PACLITAXEL   TRIM5

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PACLITAXEL   ABCC10

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18445659


    Sources:
    CIViC

  • PACLITAXEL   FNTB

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26033044


    Sources:
    PharmGKB

  • PACLITAXEL   TLE3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • PACLITAXEL   SOX10

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    PharmGKB

  • PACLITAXEL   SOD2

    Interaction Score: 0.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25495407


    Sources:
    PharmGKB

  • PACLITAXEL   TUBB1

    Interaction Score: 0.25

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name oral paclitaxel
    Novel drug target Established target
    Trial Name Abraxane

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901 19575780 17314054 17016423 17139284 1350385


    Sources:
    DTC TdgClinicalTrial ChemblInteractions TEND

  • PACLITAXEL   ACSS2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • PACLITAXEL   PGP

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    ClearityFoundationBiomarkers

  • PACLITAXEL   TUBB3

    Interaction Score: 0.21

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ClearityFoundationBiomarkers ChemblInteractions

  • PACLITAXEL   TUBA1C

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBA3D

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBB6

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBA3E

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Tubulin inhibitor

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBB2B

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBA4A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Tubulin inhibitor

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBB8

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBA1B

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBA1A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBB2A

    Interaction Score: 0.2

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBB4B

    Interaction Score: 0.19

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions

  • PACLITAXEL   TUBB

    Interaction Score: 0.17

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Tubulin inhibitor
    Direct Interaction yes

    PMIDs:
    23631389 17887662 22595423 25369367 24457094 23725535 24953821 23313639 25768699 19758808 23387901


    Sources:
    DTC ChemblInteractions TTD

  • PACLITAXEL   BCL2

    Interaction Score: 0.16

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name Abraxane
    Novel drug target Established target
    Trial Name AI-850

    PMIDs:
    23963862 17062688 17119350 16741658 16895478 17230521


    Sources:
    TdgClinicalTrial ClearityFoundationClinicalTrial TEND PharmGKB TTD

  • PACLITAXEL   MAP3K1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • PACLITAXEL   EDNRB

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16741060


    Sources:
    NCI

  • PACLITAXEL   ERCC1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25495407 17229776


    Sources:
    CIViC PharmGKB

  • PACLITAXEL   ERCC2

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19470925


    Sources:
    CIViC

  • PACLITAXEL   SLCO1B3

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26641474 26267044 21151855


    Sources:
    PharmGKB

  • PACLITAXEL   FOS

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9588740


    Sources:
    NCI

  • PACLITAXEL   GSTT1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12851839


    Sources:
    NCI

  • PACLITAXEL   LIF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11800022


    Sources:
    NCI

  • PACLITAXEL   SLC29A1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24361227


    Sources:
    PharmGKB

  • PACLITAXEL   SMAD4

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • PACLITAXEL   RRM1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23038758


    Sources:
    CIViC

  • PACLITAXEL   E2F1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16849574


    Sources:
    NCI

  • PACLITAXEL   NOTCH1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MRK-003 + Paclitaxel
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type no benefit

    PMIDs:
    25104330


    Sources:
    JAX-CKB

  • PACLITAXEL   CDKN1A

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12574211


    Sources:
    NCI

  • PACLITAXEL   NAT2

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11955677


    Sources:
    NCI

  • PACLITAXEL   BIRC5

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16211241 15347474


    Sources:
    ClearityFoundationBiomarkers NCI

  • PACLITAXEL   CYP1B1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24599932 21151855


    Sources:
    PharmGKB

  • PACLITAXEL   RAF1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21636554


    Sources:
    PharmGKB

  • PACLITAXEL   CASP7

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22441531


    Sources:
    PharmGKB

  • PACLITAXEL   CDKN2A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • PACLITAXEL   FASN

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15657900


    Sources:
    NCI

  • PACLITAXEL   GSTM1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26803611


    Sources:
    PharmGKB

  • PACLITAXEL   MMP2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9174131


    Sources:
    NCI

  • PACLITAXEL   NRG1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23390248


    Sources:
    CIViC

  • PACLITAXEL   ABCC3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18593940


    Sources:
    CIViC

  • PACLITAXEL   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Sapitinib + Paclitaxel
    Indication/Tumor Type inflammatory breast carcinoma
    Response Type sensitive

    PMIDs:
    24886365 22581822 22370314 22285168 21900837 21783417 20573926 20022809 19692680 22139083


    Sources:
    JAX-CKB CIViC PharmGKB

  • PACLITAXEL   DDIT3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8554977


    Sources:
    NCI

  • PACLITAXEL   SYK

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26096845


    Sources:
    CIViC

  • PACLITAXEL   IL2RA

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16595340


    Sources:
    NCI

  • PACLITAXEL   ERBB2

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Pdx & cell culture
    Indication/Tumor Type inflammatory breast carcinoma
    combination therapy Sapitinib + Paclitaxel

    PMIDs:
    24886365 24868024 27078022 27556950 26432108 26469692 29584549


    Sources:
    JAX-CKB CIViC

  • PACLITAXEL   CASP3

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9067280


    Sources:
    NCI

  • PACLITAXEL   PTEN

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Preclinical - Cell line xenograft
    Indication/Tumor Type prostate adenocarcinoma
    combination therapy XL147 + Paclitaxel

    PMIDs:
    25637314 25833835 25672916


    Sources:
    JAX-CKB CIViC

  • PACLITAXEL   PIK3CA

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Approval Status Clinical Study
    Response Type resistant
    Indication/Tumor Type colorectal cancer

    PMIDs:
    21216929 26245675 24170767 26469692 12761490


    Sources:
    JAX-CKB NCI

  • PACLITAXEL   CYP3A5

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26179145 20212519 16753005


    Sources:
    NCI PharmGKB

  • PACLITAXEL   KRAS

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type resistant
    combination therapy Carboplatin + Erlotinib + Paclitaxel
    Indication/Tumor Type non-small cell lung carcinoma

    PMIDs:
    26307133 21216929 16043828 22139083


    Sources:
    JAX-CKB CIViC

  • PACLITAXEL   AURKA

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12559175


    Sources:
    CIViC

  • PACLITAXEL   GSTP1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25010864


    Sources:
    CIViC

  • PACLITAXEL   BRCA2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Carboplatin + Paclitaxel + Veliparib
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • PACLITAXEL   ABCC1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • PACLITAXEL   SLCO1B1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30520341


    Sources:
    PharmGKB

  • PACLITAXEL   ABCC2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • PACLITAXEL   ATM

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Olaparib + Paclitaxel
    Indication/Tumor Type stomach cancer
    Response Type predicted – sensitive

    PMIDs:
    26282658


    Sources:
    JAX-CKB

  • PACLITAXEL   CXCL8

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9271387


    Sources:
    NCI

  • PACLITAXEL   SRC

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy KX2-391 + Paclitaxel
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    22784709


    Sources:
    JAX-CKB

  • PACLITAXEL   CDK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16020661


    Sources:
    NCI

  • PACLITAXEL   ABCG2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21151855


    Sources:
    PharmGKB

  • PACLITAXEL   JAK2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy NVP-BSK805 + paclitaxel
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type sensitive

    PMIDs:
    27075627


    Sources:
    JAX-CKB

  • PACLITAXEL   BDNF

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16778834


    Sources:
    NCI

  • PACLITAXEL   PDGFRA

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Imatinib + Carboplatin + Paclitaxel
    Indication/Tumor Type melanoma
    Response Type sensitive

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • PACLITAXEL   BRCA1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Carboplatin + Paclitaxel + Veliparib
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive

    PMIDs:
    12684687


    Sources:
    JAX-CKB NCI

  • PACLITAXEL   CYP19A1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • PACLITAXEL   MET

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type gastric adenocarcinoma
    combination therapy Crizotinib + Trastuzumab + Paclitaxel
    Evidence Type Actionable

    PMIDs:
    26432108 28514312


    Sources:
    JAX-CKB

  • PACLITAXEL   NR1I2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    agonist (activating)
    inducer (activating)

    Interaction Info:

    PMIDs:
    18839173 21151855


    Sources:
    PharmGKB

  • PACLITAXEL   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16467099 16289636 15876424


    Sources:
    DTC NCI CIViC

  • PACLITAXEL   PIK3CG

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12087097


    Sources:
    NCI

  • PACLITAXEL   OPRM1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23963862


    Sources:
    PharmGKB

  • PACLITAXEL   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ipatasertib + Paclitaxel
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • PACLITAXEL   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy MK-1775 + Carboplatin + Paclitaxel
    Indication/Tumor Type ovarian cancer
    Response Type sensitive

    PMIDs:
    16459017 24065105


    Sources:
    JAX-CKB NCI CIViC

  • PACLITAXEL   TOP2A

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Trial Name liposomal encapsulated paclitaxel (LEP)
    Novel drug target Established target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial

  • PACLITAXEL   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16890579 9187528 25398452 21151855


    Sources:
    PharmGKB

  • PACLITAXEL   GMNN

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PACLITAXEL   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TEND: PACLITAXEL

    • Version: 01-August-2011

    Alternate Names:
    PACLITAXEL Primary Drug Name

    Drug Info:
    Drug Class antineoplastic agents
    Year of Approval 1992

    Publications:

  • TdgClinicalTrial: PACLITAXEL

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: PACLITAXEL

    • Version: 14-September-2017

    Alternate Names:
    C1411 NCI drug code

    Drug Info:

    Publications:
    Medeiros et al., 2003, Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome., Int. J. Clin. Oncol.
    Nanovskaya et al., 2005, Role of P-glycoprotein in transplacental transfer of methadone., Biochem. Pharmacol.
    Ibrado et al., 1997, Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells., Cancer Res.

  • DTC: PACLITAXEL

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL428647 ChEMBL Drug ID

    Drug Info:

    Publications:
    Bio M et al., 2013, Site-specific and far-red-light-activatable prodrug of combretastatin A-4 using photo-unclick chemistry., J Med Chem
    O'Boyle NM et al., 2014, β-Lactam estrogen receptor antagonists and a dual-targeting estrogen receptor/tubulin ligand., J Med Chem
    Parrino B et al., 2015, Water-soluble isoindolo[2,1-a]quinoxalin-6-imines: in vitro antiproliferative activity and molecular mechanism(s) of action., Eur J Med Chem

  • NCI: TAXOL

    • Version: 14-September-2017

    Alternate Names:
    C1411 NCI drug code

    Drug Info:

    Publications:
    Gately et al., 1996, Cisplatin and taxol activate different signal pathways regulating cellular injury-induced expression of GADD153., Br. J. Cancer
    Abaza et al., Antisense oligodeoxynucleotide directed against c-myb has anticancer activity and potentiates the antiproliferative effect of conventional anticancer drugs acting by different mechanisms in human colorectal cancer cells., Tumour Biol.
    Yanagisawa et al., 2004, A novel interaction between kinesin and p120 modulates p120 localization and function., J. Biol. Chem.

  • JAX-CKB: Paclitaxel

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Yu et al., 2015, Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092., PLoS ONE
    Liu et al., 2013, BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models., Mol. Cancer Ther.
    Guarneri et al., 2015, Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast Cancer., Oncologist

  • JAX-CKB: paclitaxel

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Balko et al., 2016, Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence., Sci Transl Med

  • PharmGKB: paclitaxel

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Lee SY et al., 2014, Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy., Eur J Cancer
    Li Y et al., 2011, Genetic variations in multiple drug action pathways and survival in advanced stage non-small cell lung cancer treated with chemotherapy., Clin Cancer Res
    Oshiro C et al., 2009, Taxane pathway., Pharmacogenet Genomics

  • CIViC: PACLITAXEL

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Brachova P et al., 2013, The consequence of oncomorphic TP53 mutations in ovarian cancer., Int J Mol Sci
    Anand et al., 2003, AURORA-A amplification overrides the mitotic spindle assembly checkpoint, inducing resistance to Taxol., Cancer Cell
    Gréen et al., 2006, mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy., Clin. Cancer Res.

  • TTD: Taxol

    • Version: 2020.06.01

    Alternate Names:
    D0C4RB TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL428647

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • MyCancerGenomeClinicalTrial: TAXOL

    • Version: 30-February-2014

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationClinicalTrial: PACLITAXEL

    • Version: 15-June-2013

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL428647

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ClearityFoundationBiomarkers: PACLITAXEL

    • Version: 26-July-2013

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21